

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Vivo Capital VIII, LLC</u> <hr/> (Last) (First) (Middle) C/O VIVO CAPITAL LLC 505 HAMILTON AVENUE, SUITE 207 <hr/> (Street) PALO ALTO CA 94301 <hr/> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 07/17/2018	3. Issuer Name and Ticker or Trading Symbol <u>Crinetics Pharmaceuticals, Inc. [CRNX]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	54,711	I	By Vivo Capital, LLC ⁽¹⁾

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Series A Preferred Stock	(2)	(2)	Common Stock	2,560,613	0.00	I	By Vivo Capital Fund VIII, L.P. ⁽³⁾
Series A Preferred Stock	(2)	(2)	Common Stock	353,590	0.00	I	By Vivo Capital Surplus Fund VIII, L.P. ⁽³⁾
Series B Preferred Stock	(4)	(4)	Common Stock	413,040	0.00	I	By Vivo Capital Fund VIII, L.P. ⁽³⁾
Series B Preferred Stock	(4)	(4)	Common Stock	57,035	0.00	I	By Vivo Capital Surplus Fund VIII, L.P. ⁽³⁾

1. Name and Address of Reporting Person* <u>Vivo Capital VIII, LLC</u> <hr/> (Last) (First) (Middle) C/O VIVO CAPITAL LLC 505 HAMILTON AVENUE, SUITE 207 <hr/> (Street) PALO ALTO CA 94301 <hr/> (City) (State) (Zip)		
--	--	--

1. Name and Address of Reporting Person*		
Vivo Capital, LLC		
(Last)	(First)	(Middle)
505 HAMILTON AVENUE, SUITE 207		
(Street)		
PALO ALTO	CA	94301
(City) (State) (Zip)		
1. Name and Address of Reporting Person*		
Vivo Capital Fund VIII, L.P.		
(Last)	(First)	(Middle)
505 HAMILTON AVENUE, SUITE 207		
(Street)		
PALO ALTO	CA	94301
(City) (State) (Zip)		
1. Name and Address of Reporting Person*		
Vivo Capital Surplus Fund VIII, L.P.		
(Last)	(First)	(Middle)
505 HAMILTON AVENUE, SUITE 207		
(Street)		
PALO ALTO	CA	94301
(City) (State) (Zip)		

Explanation of Responses:

- Vivo Capital LLC is the management company of Vivo Capital VIII, LLC ("Vivo LLC"). The voting members of each of Vivo Capital LLC and Vivo LLC are Frank Kung, Albert Cha, Edgar Engleman, Chen Yu and Shan Fu, none of whom has individual voting or investment power with respect to these securities. Jack B. Nielsen, M.Sc., a director of the issuer, is a Managing Director at Vivo Capital LLC. Each of the above-listed individuals disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for the purposes of Section 16 or for any other purposes.
- Each of the 8,424,416 and 1,163,311 shares of Series A Preferred Stock held by Vivo Capital Fund VIII, L.P. ("VCF") and Vivo Capital Surplus Fund VIII, L.P. ("VCSF"), respectively, is convertible, at any time, at the holder's election, at a ratio of 3.29 to one share of the Issuer's common stock. In addition, effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series A Preferred Stock will automatically convert at a ratio of 3.29 to one share of the Issuer's common stock. The Series A Preferred Stock has no expiration date.
- Vivo LLC is the general partner of each of VCF and VCSF, the record holder of the securities, and disclaims beneficial ownership over such securities except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes. In addition, Albert Cha, Frank Kung, Edgar Engleman, Chen Yu and Shan Fu are managing members of Vivo LLC and may be deemed to share voting and dispositive power over the securities held by VCF and VCSF. Each of these individuals disclaims beneficial ownership over such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
- Each of the 1,358,903 and 187,648 shares of Series B Preferred Stock held by VCF and VCSF, respectively, is convertible, at any time, at the holder's election, at a ratio of 3.29 to one share of the Issuer's common stock. In addition, effective immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series B Preferred Stock will automatically convert at a ratio of 3.29 to one share of the Issuer's common stock. The Series B Preferred Stock has no expiration date.

[/s/ Albert Cha as a managing member of Vivo Capital VIII, LLC](#) 07/17/2018

[/s/ Albert Cha as a managing member of Vivo Capital LLC](#) 07/17/2018

[/s/ Albert Cha as a managing member of Vivo Capital VIII, LLC, the general partner of Vivo Capital Fund VIII, L.P.](#) 07/17/2018

[/s/ Albert Cha as a managing member of Vivo Capital VIII, LLC, the general partner of Vivo Capital Surplus Fund VIII, L.P.](#) 07/17/2018

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.